<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257893</url>
  </required_header>
  <id_info>
    <org_study_id>4959S-10</org_study_id>
    <nct_id>NCT01257893</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance in Women With Migraine</brief_title>
  <acronym>ARWM</acronym>
  <official_title>Aspirin Resistance in Women With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Headache Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wadsworth Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accumetrics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the rates of aspirin resistance (high residual&#xD;
      platelet reactivity) between women with episodic and chronic migraine and women without&#xD;
      migraine.&#xD;
&#xD;
      Emerging evidence suggests that migraineurs, especially women &lt; 45 years who have aura, have&#xD;
      an increased risk of stroke and myocardial infarction (MI, or heart attack). The mechanism&#xD;
      linking migraine, stroke and MI is unclear although increased platelet activation and&#xD;
      aggregation observed during and between migraine attacks may be a plausible theory.&#xD;
&#xD;
      Aspirin is an inexpensive, relatively safe antiplatelet drug that reduces the risk of stroke&#xD;
      and MI. Preliminary data suggest that aspirin's (325mg) therapeutic effect on platelet&#xD;
      inhibition may be reduced in migraineurs (i.e., aspirin resistance), thus limiting aspirin's&#xD;
      effectiveness at preventing stroke and MI risks in persons with migraine. Additional research&#xD;
      is warranted to confirm these findings in migraineurs because daily, low-dose aspirin 81 mg&#xD;
      is the recommended first line therapy for primary and secondary prevention of stroke and MI&#xD;
&#xD;
      The researchers hypothesize that resistance to aspirin 81mg may occur more frequently in&#xD;
      women with episodic and chronic migraine than in women without migraine. The findings may&#xD;
      have important implications for women who have migraine and use aspirin to prevent migraine&#xD;
      symptoms or comorbidities associated with migraine including stroke and MI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the hypothesis that the rate of aspirin resistance is greater in women with episodic&#xD;
      and chronic migraine than in women without migraine, a three-group, randomized, double-blind,&#xD;
      placebo-controlled, crossover design will be used to test the effects of aspirin 81 mg on&#xD;
      platelet reactivity. Subjects will be randomized to treatment order (A) aspirin 81 mg for&#xD;
      10-14 consecutive days followed by placebo for 10-14 consecutive days or (B) placebo for&#xD;
      10-14 consecutive days followed by aspirin 81 mg for 10-14 consecutive days. Other than&#xD;
      treatment order, subjects will be treated equally. Study procedures will be performed at the&#xD;
      University of Washington, and the duration of the study per subject will be approximately 28&#xD;
      days. Endpoints include: a) Aspirin Reaction Units (ARU) using a point-of-care assay&#xD;
      (VerifyNow Aspirin™; Accumetrics, San Diego, CA); b) serum thromboxane B2; and c) percent&#xD;
      platelet inhibition on aspirin. Assessment of adherence to study regimen will be assessed by&#xD;
      serum salicylate, medication diaries, and pill counts. Data will also be collected on&#xD;
      migraine frequency, burden, disability, and medications used to treat headache. Subjects will&#xD;
      maintain a migraine diary for the duration of the study (28 days). The target sample will&#xD;
      include women with episodic migraine (n=40; n=20 MA, n=20 MO), women with chronic migraine&#xD;
      (n=40) and non-migraine controls (n=40).&#xD;
&#xD;
      The specific aims of the study are as follows:&#xD;
&#xD;
        -  Compare the rate of aspirin resistance between women with and without migraine following&#xD;
           10-14 consecutive days of aspirin 81 mg treatment&#xD;
&#xD;
        -  Compare the rate of aspirin resistance between women who have episodic migraine and&#xD;
           chronic migraine following 10-14 consecutive days of aspirin 81 mg treatment&#xD;
&#xD;
        -  Compare the rate of aspirin resistance between women who have migraine with aura (MA)&#xD;
           and migraine without aura (MO) following 10-14 consecutive days of aspirin 81 mg or&#xD;
           placebo treatment&#xD;
&#xD;
        -  Compare the rate of aspirin resistance between women who have migraine with high monthly&#xD;
           migraine frequency and low monthly migraine frequency following 10-14 consecutive days&#xD;
           of aspirin 81 mg treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aspirin Reaction Units (ARU)</measure>
    <time_frame>10-14 days</time_frame>
    <description>Measurement of ARU, indicative of platelet inhibition, using the VerifyNow Aspirin Assay (Accumetrics, San Diego, CA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum thromboxane B2</measure>
    <time_frame>10-14 days</time_frame>
    <description>Aspirin acts by inhibiting production of thromboxane A2 by platelets. Thromboxane B2 is the stable product of thromboxane A2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Episodic Migraine</condition>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 81 mg aspirin per day for 10-14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (acetylsalicylic acid)</intervention_name>
    <description>Aspirin one 81 mg capsule per day for 10-14 consecutive days</description>
    <arm_group_label>Aspirin 81 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18-50 years of age, of childbearing potential&#xD;
&#xD;
          -  Able to read, speak, and understand English -- except if patient is blind, in which&#xD;
             case only the ability to understand English is required.&#xD;
&#xD;
        Episodic Migraine Group:&#xD;
&#xD;
          -  Documented diagnosis of episodic migraine for a 2-year period preceding enrollment,&#xD;
             using the International Headache Society (IHS) criteria.&#xD;
&#xD;
          -  Frequency of 2-14 migraine days in the three months prior to enrollment.&#xD;
&#xD;
          -  Equal numbers (n=20 each) will have a documented diagnosis of migraine with aura (MA)&#xD;
             and migraine without aura (MO).&#xD;
&#xD;
          -  For women who have a diagnosis of MA, focal neurologic symptoms must precede or&#xD;
             accompany the headache (aura) for at least one headache in the 12 months prior to&#xD;
             enrollment.&#xD;
&#xD;
        Chronic Migraine Group:&#xD;
&#xD;
          -  Frequency of ≥ 15 headache days per month for ≥ 3 months.&#xD;
&#xD;
          -  On at least 8 days per month for ≥ 3 months headache has fulfilled criteria for pain&#xD;
             and associated symptoms of MO.&#xD;
&#xD;
        Control group:&#xD;
&#xD;
        - No diagnosis of migraine, confirmed by the Migraine Assessment Tool.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Post-menopausal, either natural or surgical (bilateral oophorectomy)&#xD;
&#xD;
          -  Current prescribed daily medication regimen includes any of the following: warfarin,&#xD;
             glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban), antiplatelet agents&#xD;
             (clopidogrel, ticlopidine, dipyridamole), or non-steroidal anti-inflammatory drugs&#xD;
             (e.g., ibuprofen, naproxen, celecoxib), Vitamin E in doses &gt; 800 IU per day, Omega-3&#xD;
             fatty acids in doses &gt; 3 g/day, willow bark (any amount), aspirin or&#xD;
             aspirin-containing medications.&#xD;
&#xD;
          -  Aspirin intolerance or allergy, or peptic ulcer disease.&#xD;
&#xD;
          -  Platelet count &lt;150,000/µl or &gt;450,000/µl.&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
          -  History or current diagnosis of myocardial infarction, stroke, coronary artery&#xD;
             disease, peripheral arterial disease, diabetes mellitus, or renal disease.&#xD;
&#xD;
          -  Unable to tolerate washout of protocol-restricted medications and/or supplements (see&#xD;
             #3).&#xD;
&#xD;
          -  Family (first-degree relative) or patient history of bleeding or hemorrhagic disorders&#xD;
             including von Willebrand Factor Deficiency, Glanzmann Thrombasthenia, Bernard-Soulier&#xD;
             Syndrome or myeloproliferative syndromes.&#xD;
&#xD;
          -  Major surgical procedure, trauma, blood donation, or major blood loss (&gt;300 cc) within&#xD;
             30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill T. Jesurum, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy J. Fuller, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvia M. Lucas, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Murinova, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jesurum, J.T., Fuller, C.J., Lucas, S.M., Murinova, N., Truva, C.M., McGee, E.A., Reisman, M. High prevalence of aspirin resistance in migraineurs. Cephalalgia 2009; 29 (Suppl. 1): 138.</citation>
  </reference>
  <reference>
    <citation>Jesurum, J.T., Fuller, C.J., Lucas, S.M., Murinova, N., Hales, L.E., McGee, E.A. The association between migraine frequency and platelet activation in episodic migraine: a pilot study. Cephalalgia 2009; 29 (Suppl. 1); 2009.</citation>
  </reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <name_title>Jill T. Jesurum, Ph.D., Scientific Director</name_title>
    <organization>Swedish Medical Center</organization>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>chronic migraine</keyword>
  <keyword>migraine with aura</keyword>
  <keyword>migraine without aura</keyword>
  <keyword>aspirin</keyword>
  <keyword>platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

